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Activating CARD14 Mutations Are Associated with
Generalized Pustular Psoriasis but Rarely Account for
Familial Recurrence in Psoriasis Vulgaris
Dorottya M. Berki1, Lu Liu2, Siew-Eng Choon3, A. David Burden4, Christopher E.M. Grifﬁths5,
Alexander A. Navarini6, Eugene S. Tan7, Alan D. Irvine8,9, Annamari Ranki10, Takeshi Ogo11, Gabriela Petrof2,
Satveer K. Mahil1, Michael Duckworth2, Michael H. Allen2, Pasquale Vito12, Richard C. Trembath13,
John McGrath2, Catherine H. Smith2, Francesca Capon1,14 and Jonathan N. Barker2,14
Caspase recruitment family member 14 (CARD14, also known as CARMA2), is a scaffold protein that mediates
NF-κB signal transduction in skin keratinocytes. Gain-of-function CARD14 mutations have been documented in
familial forms of psoriasis vulgaris (PV) and pityriasis rubra pilaris (PRP). More recent investigations have also
implicated CARD14 in the pathogenesis of pustular psoriasis. Follow-up studies, however, have been limited, so
that it is not clear to what extent CARD14 alleles account for the above conditions. Here, we sought to address
this question by carrying out a systematic CARD14 analysis in an extended patient cohort (n= 416). We observed
no disease alleles in subjects with familial PV (n= 159), erythrodermic psoriasis (n= 23), acral pustular psoriasis
(n= 100), or sporadic PRP (n= 29). Conversely, our analysis of 105 individuals with generalized pustular psoriasis
(GPP) identiﬁed a low-frequency variant (p.Asp176His) that causes constitutive CARD14 oligomerization and
shows a signiﬁcant association with GPP in Asian populations (P= 8.4× 10− 5; odds ratio= 6.4). These data indicate
that the analysis of CARD14 mutations could help stratify pustular psoriasis cohorts but would be mostly
uninformative in the context of psoriasis and sporadic PRP.
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INTRODUCTION
Caspase recruitment family member 14 (CARD14, also known
as CARMA2) is a conserved scaffold protein that mediates
TRAF2-dependent activation of NF-κB signaling (Scudiero
et al., 2011). The gene is most prominently expressed in
the skin, as transcript levels are high in keratinocytes and
moderately abundant in dermal endothelial cells (Fuchs-Telem
et al., 2012; Harden et al., 2014). Conversely, CARD14 mRNA
is virtually undetectable in T-lymphocytes and monocytes,
suggesting that the gene is speciﬁcally required for the
maintenance of skin immune homeostasis (Fuchs-Telem
et al., 2012; Harden et al., 2014). In keeping with this
notion, gain-of-function CARD14 mutations have been linked
to a number of inﬂammatory dermatoses.
Disease alleles resulting in enhanced NF-κB signaling were
ﬁrst described in two multi-generation pedigrees where
psoriasis vulgaris (PV) segregated as an autosomal dominant
trait (Jordan et al., 2012b). Three further activating mutations
were subsequently reported in individuals with familial
pityriasis rubra pilaris (PRP), a papulosquamous condition
phenotypically related to psoriasis (Fuchs-Telem et al., 2012).
Finally, the analysis of a small Japanese resource identiﬁed
a tentative association between a CARD14 variant
(p.Asp176His) and a generalized pustular psoriasis (GPP), a
rare neutrophilic dermatosis that often presents with systemic
upset and concurrent PV (Sugiura et al., 2014).
Of note, the follow-up to the ﬁndings originally obtained in
familial PV has been very limited, with a single survey of
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seven North-African pedigrees published in the literature
(Ammar et al., 2013). Likewise, studies of CARD14 in
PRP have mostly been restricted to cohorts recruited in the
Middle East (Eytan et al., 2014), and the association between
p.Asp176His and generalized pustular psoriasis has yet to be
validated, as it was only supported by marginal statistical
signiﬁcance. Thus, large gaps remain in our understanding of
the phenotypes that are caused by CARD14 mutations, and it
is not clear whether the genetic analysis of this locus might
aid disease stratiﬁcation.
Here, we have sought to address this issue by investigating
an extended and an ethnically diverse patient resource.
We found that CARD14 alleles are unlikely to account for a
signiﬁcant proportion of familial PV or sporadic PRP cases.
Conversely, we demonstrated that the p.Asp176His variant
has a substantial impact on protein function and is strongly
associated with generalized pustular psoriasis in the Chinese
and Japanese populations.
RESULTS
CARD14 mutations do not have a signiﬁcant role in the
pathogenesis of familial PV, sporadic PRP, or acral pustular
psoriasis
As all CARD14 mutations described to date cluster to exons 3
and 4 (Fuchs-Telem et al., 2012; Jordan et al., 2012b; Eytan
et al., 2014; Sugiura et al., 2014), we initially focused
our genetic screening on this region. We sequenced the two
exons in a total of 416 patients, affected by acral pustular
psoriasis (APP; n=100), erythrodermic psoriasis (n= 23),
familial PV (n= 159), GPP (n= 105), or PRP (n= 29)
(Table 1, Supplementary Table 1 online). Importantly, our
calculations showed that all data sets had adequate power
(480%) to detect mutations accounting for 45% of disease
cases (Figure 1). In fact, the power of the familial PV, APP, and
GPP samples exceeded 95% (Figure 1). This is in keeping
with previous analyses of the APP and GPP cohorts, which
allowed us to identify a number of low-frequency mutations
(Setta-Kaffetzi et al., 2013; Setta-Kaffetzi et al., 2014).
Despite the evidence for adequate power, we could not
detect any deleterious alleles among patients affected by APP,
familial PV, or erythrodermic psoriasis (Tables 2A and 2B). In
fact, the only coding change observed in these data sets was a
p.Ser200Asn substitution, which was identiﬁed in two cases
of APP and four patients affected by familial PV (Table 2A).
This variant was, however, classiﬁed as benign by multiple
pathogenicity prediction algorithms. Moreover, its frequency
in APP (1.0%) and familial PV subjects (1.25%) did not
exceed that observed in European controls (1.3%, according
to the data generated by the Exome Aggregation Consortium).
The screening of the PRP sample revealed a single
change with pathogenic potential (p.Gln136Lys; Table 2A).
However, this was observed in a patient who under-
went parallel investigations of the GJB4 gene to explore a
differential diagnosis of erythrokeratoderma. Given that a
damaging p.Cys169Trp change was identiﬁed in GJB4, it was
Table 1. Patient resource summary statistics
Disease
N. of
cases Sex Ethnicity
Acral pustular psoriasis1 100 34M, 66F North-European
Erythrodermic psoriasis 23 18M, 5F North-European
Familial psoriasis vulgaris 159 78M, 81F North-European
Generalised pustular
psoriasis
105 34M, 71F North-European
(n= 12 )
Chinese (n= 24 )
Malay (n=52)
Indian (n= 17)
Pityriasis rubra pilaris 29 16M, 13F North-European
(n= 24)
Afro-Caribbean
(n= 2)
Unknown (n=3)
Total 416 180M, 236F North-European
(n= 318)
Asian (n=93)
Afro-Caribbean
(n= 2)
Unknown (n=3)
Abbreviations: F, Female; M, Male.
1Including Palmar Plantar Pustulosis (n=92) and Acrodermatitis Continua
of Hallopeau (n=8).
Po
w
er
Proportion of cases harboring a mutation
Acral pustular
psoriasis
Erythrodermic
psoriasis 
1% 2% 4% 6% 8% 10% 12%
0
0.2
0.4
0.6
0.8
1 Familial psoriasis
vulgaris 
Generalized
pustular psoriasis 
Pityriasis rubra
pilaris 
Figure 1. Power calculations. A binomial calculation calculator was used to estimate the power to detect CARD14 mutations accounting for variable proportions
of disease cases. This demonstrated that sequencing exons 3 and 4 in the various patient cohorts would have480% power to uncover mutations found in45%
of disease cases.
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not possible to reach a ﬁrm conclusion as to which variant
was causing the disease phenotype.
Importantly, sequencing of the entire CARD14 coding
region in a representative patient subset (n= 82; Supplemen-
tary Table 2 online) did not identify any additional changes
with deleterious potential. Thus, our ﬁndings indicate that
CARD14 disease alleles are unlikely to account for a signi-
ﬁcant proportion of familial PV, sporadic PRP, or APP cases.
The CARD14 p.Asp176His variant is associated with generalized
pustular psoriasis in the Chinese and Japanese populations
The analysis of the generalized pustular psoriasis resource
identiﬁed three unrelated subjects of Chinese descent, who
carried a deleterious p.Asp176His substitution (Figure 2a;
Table 2A; Supplementary Table 3 online). Of note, one of the
patients had inherited the variant from a maternal aunt, who
was also affected by GPP. Although the change occurs at low
frequency in the Chinese population, we found that it was
more common in GPP cases compared with controls (6.2%
vs. 1.0%, P= 0.03; Table 3). As these observations mirror
those previously reported in a small Japanese data set (Sugiura
et al., 2014), we undertook a meta-analysis of the two studies.
To maximize statistical power, we increased by 4-fold the size
of the Japanese control resource by obtaining frequency data
for an additional 322 individuals (104 subjects sequenced by
the 1000 Genomes Project and 218 screened in-house). This
validated the association with the p.Asp176His substitution
(P=0.008) and showed that the Japanese and Chinese data
sets were genetically homogeneous (I2:0%). The subsequent
meta-analysis of the two studies also demonstrated that the p.
Asp176His change confers a very substantial increase in
disease risk (odds ratio: 6.4; 95% conﬁdence interval: 2.5–
16.1; P= 8.4× 10−5).
As p.Asp176His occurs on the background of a single
haplotype in the Japanese population (Sugiura et al., 2014),
we typed four tagging single nucleotide polymorphisms in our
mutation bearing patients, in order to establish whether
they carried the same ancestral chromosome. We found that
three subjects were homozygous and one likely heterozygous
for the same intragenic haplotype that was described in the
Japanese individuals carrying the p.Asp176His variant
(Supplementary Table 4 online). Thus, our data strongly
support the notion that the spread of the mutation across East
Asia is the result of a founder effect.
Sequencing of the entire CARD14 coding region in a
representative patient subset (n= 15) did not uncover any
further disease alleles, indicating that the association with
GPP is speciﬁc to the p.Asp176His change.
Table 2A. Rare coding variants detected in the study resource
Change (rs ID) Patient phenotype
Pathogenicity prediction
SIFT Polyphen-2 PROVEAN
Mutation
Taster Align GVGD
CADD
score1 CONSENSUS2
p.Met119Arg (novel) PRP (n= 1) Tolerated Benign Neutral Disease
Causing
Pathogenic Damaging NEUTRAL
p.Gln136Lys (novel) PRP (n= 1) Damaging Probably
Damaging
Neutral Disease
Causing
Pathogenic Damaging DAMAGING
p.Glu168Lys (novel) GPP (n= 1) Tolerated Benign Neutral Polymorphism Pathogenic Neutral NEUTRAL
p.Asp176His
(rs144475004)
GPP (n= 3) Damaging Probably
damaging
Neutral Disease
Causing
Pathogenic Damaging DAMAGING
p.Ser200Asn
(rs114688446)
PV (n=4) APP
(n=2)
Tolerated Benign Neutral Polymorphism Likely Benign Neutral NEUTRAL
p.Ala216Thr (novel) GPP (n= 1) Tolerated Benign Neutral Polymorphism Likely
Pathogenic
Neutral NEUTRAL
1Although the CADD algorithm does not return qualitative pathogenicity predictions, scores 415.0 are generally considered as evidence of pathogenicity.
The only variant that is likely to be disease causing (p.Asp176His) is highlighted in bold.
2Variants were classiﬁed as pathogenic if they were predicted to be deleterious by at least four algorithms.
Table 2B. Rare splicing variant detected in the study resource
Change (rs ID) Patient phenotype
Pathogenicity prediction
Max entropy SROOGLE Senepathy MutationTaster CADD score1 CONSENSUS2
c.2569+4T4C (rs146678380) APP (n=1) Neutral Neutral Neutral Disease Causing Neutral NEUTRAL
Abbreviations: APP, acral pustular psoriasis; GPP, generalized pustular psoriasis; PRP, pityriasis rubra pilaris; PV, psoriasis vulgaris.
1Although the CADD algorithm does not return qualitative pathogenicity predictions, scores 415.0 are generally considered as evidence of pathogenicity.
The only variant that is likely to be disease causing (p.Asp176His) is highlighted in bold.
2Variants were classiﬁed as pathogenic if they were predicted to be deleterious by at least four algorithms.
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The p.Asp176His variant is a deleterious allele associated with
constitutive CARD14 oligomerization
To investigate the functional consequences of the p.Asp176His
substitution, we ﬁrst used bioinformatics to assess its potential
effect on the coiled-coil (CC) domain encoded by exons 3
and 4. We found that the change from a negatively charged
aspartic acid to a basic histidine signiﬁcantly reduces the
likelihood of CC formation (Figure 2b). This effect is compar-
able with the predicted impact of p.Leu156Pro and
p.Glu138Ala (Figure 2b), two disease alleles previously
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Figure 2. The p.Asp176His substitution causes spontaneous CARD14 oligomerization. (a) Chromatogram showing the p.Asp176His (c.526G4C) change,
which is predicted to disrupt coiled-coil (CC) formation (b). (c) Western blotting of total cell lysates shows comparable amounts of wild-type and mutant
CARD14. (d and e) Western blotting and densitometric analysis of soluble proteins shows reduced accumulation of CC mutants (p.Glu138Ala, p.Pro156Leu,
p.Asp176His) compared with wild-type CARD14 and the non-CC mutant p.Gly117Ser. (f and g) Western blotting and densitometric analysis of insoluble proteins
shows enhanced aggregation of CC mutants compared with wild-type CARD14 and p.Gly117Ser. All densitometry data are expressed as mean± SD of at
least two independent experiments. Comparable results were obtained when the levels of soluble (or insoluble) protein were normalized to total CARD14,
rather than β-actin. *Po0.05; ***Po0.001; ****Po0.0001. WT, wild-type.
Table 3. Genetic analysis of the p.Asp176His variant
Allele counts (%)
Ethnicity Cases Controls P value
Japanese 4/42 (9.5%) 14/844 (1.7%) 0.008
Chinese1 3/48 (6.2%) 4/400 (1.0%) 0.030
Meta-analysis 8.4×10−5
1As the association analysis was carried out on unrelated cases, the aunt of
patient T014369 was excluded from the data set.
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associated with PRP and psoriasis (Fuchs-Telem et al., 2012;
Jordan et al., 2012b).
Of note, the CC domain of CARD11 (a well-characterized
CARD14 paralogue) keeps the protein in an inactive confor-
mation, which, in the absence of inﬂammatory stimuli,
precludes auto-oligomerization and downstream signal trans-
duction (Lamason et al., 2010). In fact, gain-of-function muta-
tions within the CC of CARD11 cause spontaneous protein
aggregation and constitutive activation of NF-κB signaling,
leading to the onset of diffuse large B-cell lymphoma (Lenz
et al., 2008).
To investigate the possibility that the p.Asp176His
substitution may also promote protein oligomerization, we
transfected HEK293 cells with wild-type or mutant FLAG-
CARD14 and monitored recombinant protein levels with an
anti-FLAG antibody. Although western blotting of whole-cell
extracts showed comparable transfection efﬁciencies for the
two constructs (Figure 2c), the analysis of soluble proteins
demonstrated that the p.Asp176His change was associated
with a signiﬁcant decrease in the levels of free CARD14 (Figure
2d and e). This suggested that the mutant protein was forming
insoluble oligomers. To validate this hypothesis, we used the
anti-FLAG antibody to analyze the insoluble fraction of the cell
extracts. As predicted, we found that CARD14 aggregates were
signiﬁcantly more abundant in the cells that had been
transfected with the p.Asp176His cDNA (Figure 2f and g).
Interestingly, a similar effect was noted for the constructs
harboring the p.Leu156Pro and p.Glu138Ala disease alleles
(Figure 2d, e, f, and g). Thus, our ﬁndings indicate that the
pathogenic potential of the p.Asp176His change is comparable
with that of previously validated mutations.
DISCUSSION
In the last few years, CARD14 mutations have been asso-
ciated with a range of inﬂammatory skin disorders, including
familial psoriasis and clinically related conditions such as PRP
and generalized pustular psoriasis (Fuchs-Telem et al., 2012;
Jordan et al., 2012b; Sugiura et al., 2014). Although these
ﬁndings have highlighted CARD14 as a key regulator of skin
immune homeostasis, their applicability to clinical practice
has been limited. Very little information is available on
mutation frequencies in different conditions or ethnic groups,
so that it is unclear whether CARD14 screening would aid the
diagnosis or stratiﬁcation of inﬂammatory dermatoses. Here,
we sought to address this issue by analyzing a sizeable and a
well-characterized patient resource, recruited in Europe and
East Asia.
We ﬁrst examined a familial PV cohort including 4150
unrelated cases. Despite the signiﬁcant power of this data set,
we could not identify previously unreported disease alleles or
detect any of the mutations reported in previous studies (Jordan
et al., 2012a; Jordan et al., 2012b). Although it could be argued
that our deﬁnition of the phenotype allowed the inclusion of
many affected sib-pairs who were unlikely to suffer from
monogenic psoriasis, our resource also comprised 51 families
with four or more affected individuals (Supplementary Table 1
online). Thus, our results indicate that Mendelian forms of
psoriasis are likely to be genetically heterogeneous, with
CARD14 mutations accounting for a small minority of cases.
The subsequent analysis of the PRP cohort generated
similarly negative results, validating the emerging notion that
CARD14 mutations do not contribute to sporadic forms of the
disease (Eytan et al., 2014). Although the idea that CARD14
has a role in the pathogenesis of PV and PRP is supported by
observations of gene overexpression in patient skin and by the
results of genome-wide association studies (Tsoi et al., 2012;
Eytan et al., 2014), our ﬁndings indicate that screening this
locus for deleterious mutations is unlikely to help the
stratiﬁcation of patient resources.
The analysis of the GPP data set demonstrated a signiﬁcant
association with a non-conservative amino acid substitution
(p.Asp176His) that is only found in Asian populations.
The functional characterization of this nucleotide change
indicated that it is likely to affect CC formation, leading to the
loss of CARD14 auto-inhibition and spontaneous protein
oligomerization. Although we did not formally demonstrate
that these abnormalities result in enhanced transcription of
NF-κB target genes, this outcome is supported by several lines
of evidence. First of all, it has been shown that CARD11
oligomerization levels strongly correlate with increased
NF-κB activation (Lenz et al., 2008). Second, the effect of
p.Asp176His on CC formation is comparable with that of
p.Leu156Pro and p.Glu138Ala, which have been extensively
characterized and linked to abnormal NF-κB signaling in vitro
and ex vivo (Fuchs-Telem et al., 2012; Jordan et al., 2012b;
Harden et al., 2014). Finally, a systematic analysis of rare
CARD14 variants has shown that overexpression of
p.Asp176His mutant constructs results in increased NF-κB
reporter activity (Jordan et al., 2012a). Thus, our ﬁndings
validate p.Asp176His as a deleterious gain-of-function allele.
Of interest, Mossner et al. (2015) have very recently
observed the p.Asp176His mutation in two APP cases
recruited in Estonia. As the p.Asp176His substitution was
not detected in any of the European data sets sequenced by
the 1000 Genomes Project, it is not surprising that the variant
did not appear in our APP cohort. In fact, its presence among
Estonian patients is likely to reﬂect the distinctive population
history of the Baltic countries. In this context, the analysis of
p.Asp176His in Asian data sets will be required to conﬁrm the
association with APP and provide further evidence for a
genetic overlap between generalized and localized pustular
psoriasis (Setta-Kaffetzi et al., 2013).
Although the evidence presented here strongly supports a
pathogenic role for p.Asp176His, no association with GPP
was observed in a recent analysis of a Han Chinese resource
(Qin et al., 2014). It is interesting, however, that none of the
cases that were examined had been screened for mutations in
IL36RN, the major genetic determinant of GPP (Onoufriadis
et al., 2011). Conversely, both our study and the analysis
carried out by Sugiura et al. (2014) were restricted to IL36RN-
negative cases. Thus, our results support the notion that the
sequential screening of disease genes will enhance the power
to detect pathogenic mutations and facilitate the stratiﬁcation
of GPP cohorts.
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MATERIALS AND METHODS
Subjects
This study was undertaken in accordance with the principles
of the Declaration of Helsinki and with the approval of the
ethics committees of all participating institutions. Patients affected
by PV, erythrodermic psoriasis, GPP, and APP (including both
Acrodermatitis Continua of Hallopeau and Palmar Plantar Pustulosis)
were ascertained as described elsewhere (Berki et al., 2014; Hussain
et al., 2015). PRP was diagnosed on the basis of established criteria
(Judge et al., 2004). All patients with pustular psoriasis had been
previously screened for IL36RN and AP1S3 mutations, so as to
exclude any subjects carrying disease alleles at known loci
(Onoufriadis et al., 2011; Setta-Kaffetzi et al., 2014). Individuals
who were affected by PV and had at least one ﬁrst-degree relative
with the same disease were considered cases of familial PV
(Supplementary Table 1 online). The demographics of the various
patient cohorts are summarized in Table 1.
Allele frequency data for 208 unrelated Chinese controls were
initially collated from the 1,000 Genome Project (CHB and CHS data
sets) (Abecasis et al., 2012). To match the genetic make-up of
cases, eight individuals with IL36RN mutations were subsequently
excluded from the association analysis. Allele frequency data for
422 independent Japanese controls were obtained from the 1,000
Genome Project (JPT data set, n= 104), the work published by
Sugiura et al. (n= 100) (Sugiura et al., 2014), and from the analysis of
218 healthy individuals, recruited at the National Cerebral and
Cardiovascular Center in Osaka (Japan) and genotyped in house by
Sanger Sequencing. None of the above individuals carried IL36RN
mutations. Allele frequency data for the European population were
obtained by mining the data generated from the Exome Aggregation
Consortium (http://exac.broadinstitute.org/).
All study participants granted their written informed consent.
Sanger sequencing and pathogenicity predictions
Primers were designed to amplify all CARD14 coding exons
and exon–intron junctions, as well as the genomic regions
spanning haplotype tagging single nucleotide polymorphisms
(Supplementary Table 5 online). Sequenced PCR products were
loaded on an ABI3730xl DNA Analyzer (Applied Biosystems,
Waltham, MA), and nucleotide changes were detected using
Sequencher 4.10.1 (Gene Codes Corporation, Ann Arbor, MI). The
pathogenic potential of non-synonymous sequence variants occur-
ring with a minor allele frequency o2% was assessed with the
following programs: SIFT (Kumar et al., 2009), PolyPhen-2 (Adzhubei
et al., 2013), PROVEAN (Choi et al., 2012), MutationTaster (Schwarz
et al., 2010), CADD (Kircher et al., 2014), Align GVGD (Mathe et al.,
2006), SROOGLE (which was also used to compute Senepathy
scores) (Schwartz et al., 2009), and MaxEntScan (Yeo and Burge,
2004). The impact of damaging nucleotide changes on CC
domains was further investigated with the NCOILS 1.0 software
(Lupas et al., 1991).
Site-directed mutagenesis, cell culture, and transfection
The previously described CARMA2-sh construct (Scudiero et al.,
2011) was used as a template for site-directed mutagenesis, as it
encodes the CARD14 isoform with the highest expression in the skin
(Jordan et al., 2012b). Reactions were prepared using the
QuikChange Lightning Site Directed mutagenesis Kit (Agilent, Santa
Clara, CA) and the primers listed in Supplementary Table 6 online.
The integrity of all constructs was veriﬁed by Sanger sequencing of
the CARD14/CARMA2 coding region, FLAG tag, CMV promoter, and
BGH poly-adenylation signal. HEK293 cells were grown in DMEM
and supplemented with 1% penicillin/streptomycin and 10% fetal
calf serum (all from Life Technologies, Carlsbad, CA). Cells were
seeded on 12-well plates at a concentration of 2.5× 105 per ml and
transfected with the indicated constructs, using Lipofectamine 2000
(Life Technologies). All cultures were harvested 48 hours after
transfection.
Western blotting and densitometry
Whole-cell protein extracts were prepared by treating cells with a
denaturing lysis buffer (5% SDS, 200Mm Tris-HCl pH 6.8, 1 mM
EDTA, 1.5% β-Mercaptoethanol, 8M Urea, and 1× Complete
Protease Inhibitor Cocktail (Roche, Basel, Switzerland)). For the
analysis of the soluble and insoluble fractions, cells were initially
incubated with a non-denaturing buffer (50 mM Tris-HCl pH 7.4,
50mM NaCl, 5 mM EDTA, 10% Glycerol, 1% NP40, and 1×
Complete Protease Inhibitor Cocktail)and centrifuged for 15minutes
at 13,000 r.p.m., at 4 °C. The supernatant was then stored as a
soluble fraction, whereas the pellets containing the insoluble protein
aggregates were lysed with the denaturing lysis buffer. Following
PAGE and transfer to nitrocellulose membranes, blots were probed
with 1:2,500 mouse monoclonal anti-FLAG (Sigma-Aldrich, St Louis,
MO) and 1:1,000 rabbit polyclonal anti β-actin (Cell Signaling
Technology, Beverly, MA) antibodies. Autoradiography ﬁlms were
scanned, and densitometric analysis was undertaken with the Image J
software (Schneider et al., 2012).
Statistical analyses
Power calculations were implemented with the binomial
probability calculator available at stattrek.com/online-calculator/
binomial.aspx. The frequency of the p.Asp176His substitution
was compared in cases versus controls with Fisher’s exact test.
The meta-analysis of two association studies was undertaken by
using the RevMan 5.2 software (Cochrane Collaboration T, 2012) to
calculate a weighted pooled odds ratio and Z score. The
densitometry data were analyzed with GraphPad Prism 6.0
(GraphPad Software, La Jolla, CA) by one-way analysis of variance
followed by the Dunnett’s post-test. P valueso0.05 were considered
statistically signiﬁcant.
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